DDInter1423 DDInter1628
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) interacts with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) resembles {v} (Compound) Thiopental
Thiopental {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) resembles {v} (Compound) Butabarbital
Butabarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) interacts with {v} (Gene) NFKB1
NFKB1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) interacts with {v} (Gene) AKT1
AKT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) binds {v} (Gene) GABRA5
GABRA5 {u} (Gene) regulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) regulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Pentobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) interacts with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Pentobarbital (Compound) resembles Thiopental (Compound) and Thiopental (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Pentobarbital (Compound) resembles Butabarbital (Compound) and Butabarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) interacts with NFKB1 (Gene) and NFKB1 (Gene) is upregulated by Ruxolitinib (Compound)
Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) interacts with AKT1 (Gene) and AKT1 (Gene) is downregulated by Ruxolitinib (Compound)
Pentobarbital (Compound) binds GABRA5 (Gene) and GABRA5 (Gene) regulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Ruxolitinib (Compound)
Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) regulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Ruxolitinib (Compound)